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Introduction {#sec1}
============

The tricarboxylic acid (TCA) cycle enzyme fumarate hydratase (FH) catalyzes the reversible hydration of fumarate to malate. While homozygous mutations of *FH* leads to fumaric aciduria (OMIM: [606812](606812){#intref0010}), a lethal metabolic disorder, its heterozygous mutations cause hereditary leiomyomatosis and renal cell cancer (HLRCC), a cancer syndrome characterized by uterine fibroids, cutaneous leiomyoma, and type 2 papillary renal cell cancer ([@bib27]). The oncogenic properties of *FH* loss have been mostly ascribed to the intracellular accumulation of fumarate. High levels of this metabolite inhibit hypoxia inducible factors (HIF) prolyl hydroxylases, leading to HIF stabilization ([@bib12]). Furthermore, fumarate causes the non-enzymatic covalent modification of reactive cysteine residues in proteins, a process known as succination ([@bib3]). This novel post-translation modification can alter protein function ([@bib25]), and it has been suggested to inactivate kelch-like ECH associated protein 1 (KEAP1), leading to the upregulation of an antioxidant response mediated by the transcription factor nuclear factor, erythroid 2 like 2 (NFE2L2) ([@bib1], [@bib19]). We also demonstrated that fumarate leads to the epigenetic suppression of a family of anti-metastatic microRNAs, *MIR200*, leading to an epithelial-to-mesenchymal transition, a phenotypic switch that promotes tumor initiation and metastasis ([@bib23]).

Because of its role as key enzyme of the TCA cycle, FH deficiency leads to profound metabolic changes, including decreased mitochondrial respiration ([@bib9], [@bib30], [@bib31]), alteration of TCA cycle functionality ([@bib9]), and reversal of the urea cycle ([@bib33]). However, the interplay between loss of FH, increased fumarate levels, and different aspects of mitochondrial biology is still unclear. Here, we investigate the effects of FH deficiency on mitochondrial function and show that FH loss leads to a complex dysregulation of the respiratory chain (RC), by affecting multiple RC complexes. Our results uncover unexpected bioenergetic features of FH-deficient cells that could explain their ability to survive under low oxygen, a condition experienced by areas of most solid tumors.

Results {#sec2}
=======

Loss of FH Leads to Respiratory Dysfunction {#sec2.1}
-------------------------------------------

We began this investigation by assessing the respiratory phenotype of mouse and human FH-deficient cells. Mouse epithelial kidney cells were obtained from *Fh1* conditional knockout animals and included Fh1-proficient cells (*Fh1*^*fl/fl*^) and two Fh1-deficient clones, *Fh1*^−/−*CL1*^ and *Fh1*^−/−*CL19*^ ([@bib9]). An Fh1-reconstituted cell line (*Fh1*^−/−^*+pFh1-GFP*) was generated to determine the effects of restoration of Fh1 activity on an Fh1-deficient background ([@bib23]). Human FH-deficient cell lines included UOK262 ([@bib30]) and a previously generated FH-reconstituted isogenic cell line, UOK262pFH ([@bib9]). In accordance with previous work ([@bib9]), Fh1-deficient cells exhibited a decreased basal respiration ([Figure 1](#fig1){ref-type="fig"}A). Furthermore, the protonophore carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone (FCCP) failed to increase respiration of Fh1-deficient cells, indicating a defect in maximal respiratory capacity ([Figure 1](#fig1){ref-type="fig"}B). Importantly, complementation of Fh1 restored normal levels of basal and maximal respiratory capacity ([Figures 1](#fig1){ref-type="fig"}A and 1B), indicating that the respiratory defects are reversible and depend on Fh1.Figure 1Fh1-Deficient Cells Display Defects in RC Complexes I and II(A) Basal respiration in the indicated mouse cells. Data are normalized for total protein content and displayed as mean ± SEM. One-way ANOVA test was applied to assess the difference in the groups.(B) Oxygen consumption rate (OCR) in response to increasing concentrations of FCCP followed by antimycin. Data are normalized for total protein content and displayed as mean ± SEM.(C) Cell growth of indicated cell lines in 25 mM galactose (squares) or glucose (circles). Data are represented as mean ± SD.(D--G) Complex I- (D), complex II- (E), complex III- (F), and complex IV- (G) driven respiration in the indicated cell lines after subtraction of inhibitor-insensitive respiration values measured after the addition of substrates. Substrates to drive respiration and concentrations of drugs used are indicated in [Figure S1](#mmc1){ref-type="supplementary-material"}. Data were generated from at least 3 independent experiments and presented as mean ± SEM. One-way ANOVA test was applied to assess the difference in the groups. n.s., not significant.

The extent of mitochondrial dysfunction was assessed further by growing cells in a glucose-deficient medium supplemented with galactose, the catabolism of which enhances oxidative metabolism. Mouse and human FH-deficient cells could not grow in the glucose-free galactose-supplemented medium ([Figures 1](#fig1){ref-type="fig"}C and [S1](#mmc1){ref-type="supplementary-material"}A), suggesting that they are unable to further increase mitochondrial function for energy generation. The expression of FH in UOK262 cells did not restore their capacity to grow in galactose ([Figure S1](#mmc1){ref-type="supplementary-material"}A), likely because they maintain high rates of glycolysis despite restoration of their mitochondrial function ([@bib9]). Overall, these results indicate that the loss of FH causes a profound mitochondrial dysfunction.

We then investigated the mechanisms behind the respiratory defects in FH-deficient cells. To this end, we measured cell respiration upon cell permeabilization with recombinant cytolysin protein (PMP), which selectively permeabilizes the plasma membrane, but not the mitochondrial membranes ([@bib22]), enabling the determination of the activity of individual RC components. In Fh1-deficient mouse cells, RC complex I activity was reduced to about 30% of that of *Fh1*-proficient cells ([Figures 1](#fig1){ref-type="fig"}D and [S1](#mmc1){ref-type="supplementary-material"}B). In addition, Fh1-deficient mouse cells displayed a loss of complex II activity ([Figures 1](#fig1){ref-type="fig"}E and [S1](#mmc1){ref-type="supplementary-material"}C), whereas the activity of RC complexes III and IV was not significantly altered ([Figures 1](#fig1){ref-type="fig"}F, 1G, [S1](#mmc1){ref-type="supplementary-material"}D, and S1E). Compared to mouse Fh1-deficient cells, UOK262 cells displayed a more pronounced respiratory defect. Indeed, alongside defective RC complex I and complex II ([Figures S1](#mmc1){ref-type="supplementary-material"}F and S1G), UOK262 cells exhibited diminished complex IV activity compared to the FH-reconstituted cell line ([Figure S1](#mmc1){ref-type="supplementary-material"}H). In summary, these data indicate that human and mouse FH-deficient cells exhibit defects in RC complexes I and II and that the human cells also exhibit defective RC complex IV.

High Levels of Fumarate Inhibit Complex II but Not Complex I {#sec2.2}
------------------------------------------------------------

The observation that respiration is impaired in PMP-permeabilized Fh1-deficient cells, in which mitochondria are intact but exposed to exogenous substrates, suggested an intrinsic dysregulation of RC complexes. Importantly, an in-gel flavin-site complex I activity assay performed on blue native gels ([Figure 2](#fig2){ref-type="fig"}A) confirmed intrinsic defects in complex I, whose activity was reduced to 30% in Fh1-deficient cells. We then tested whether fumarate, which accumulates at very high levels in these cells, affects complex I activity. To this aim, isolated mitochondrial membranes from bovine heart mitochondria were incubated with increasing doses of fumarate. Neither fumarate nor its cell-permeable derivative monomethyl-fumarate (MMF) affected complex I-mediated respiration, even at high concentration ([Figure 2](#fig2){ref-type="fig"}B). These results confirmed the defects in complex I in Fh1-defcient cells but excluded a direct effect of fumarate on this RC complex.Figure 2Fumarate Inhibits Complex II, but Not Complex I, Activity(A) Representative blue native in-gel complex I activity assay in the indicated cell lines. Data were obtained from 3 independent experiments and are presented as mean ± SEM. One-way ANOVA test was applied using Dunnett's multiple comparison test.(B) Complex I activity in mitochondrial membranes from bovine heart in the presence of the indicated concentration of fumarate and monomethyl-fumarate (MMF). Data are normalized to vehicle-treated condition and presented as mean ± SD from 4 replicates.(C) Succinate-Quinol Reductase (SQR) activity of complex II in the indicated cell lines. Values are presented as mean ± SEM.(D) Concentration of fumarate in the SQR assays showed in (C). Values are presented as mean ± SEM.(E) SQR activity of complex II in the presence of the indicated concentrations of succinate and increasing concentration of fumarate. Values are presented as mean ± SD.(F) Michealis-Menten representation of SQR activity of complex II in the presence of different concentrations of fumarate and succinate. Values are presented as mean ± SD.(G) Calculated V~max~ of complex II and K~M~ of complex II for succinate, as a function of fumarate concentration. Data were obtained from 2 independent experiments.

We also investigated the effects of fumarate on complex II. To this end, we measured the succinate-ubiquinone oxidoreductase (SQR) activity of complex II in cells incubated with a detergent that solubilizes the mitochondrial membranes, releasing matrix fumarate. Surprisingly, we found that complex II activity is not decreased in this assay ([Figures 2](#fig2){ref-type="fig"}C), in which fumarate levels are in the low micromolar range in Fh1-deficient cells ([Figure 2](#fig2){ref-type="fig"}D). Fumarate and succinate bind with similar affinity to the succinate-binding site of succinate dehydrogenase (SDH) A ([@bib10]). Hence, because the intracellular concentration of fumarate in our Fh1-deficient mouse cells is approximately 10 mM, 10-fold higher than succinate ([@bib9]), it is likely that the concentration of fumarate in the mitochondrial matrix is similarly elevated and that fumarate blocks the access of succinate to the SDHA active site. Indeed, we found that SQR activity is markedly decreased by fumarate in a concentration-dependent fashion ([Figure 2](#fig2){ref-type="fig"}E). This inhibition of SDH by fumarate is consistent with a mixed inhibition model ([Figures 2](#fig2){ref-type="fig"}F and 2G), supporting the hypothesis that accumulation of fumarate decreases SDH-driven respiration in Fh1-deficient cells by competing with succinate. In summary, these results indicate that, while fumarate has no direct inhibitory effects on complex I, it suppresses complex II activity by product inhibition.

RC Protein Abundance in FH-Deficient Cells {#sec2.3}
------------------------------------------

To investigate whether changes in RC activity were associated with specific depletion of RC complexes, we performed tandem mass tagging (TMT) quantitative proteomics ([@bib15], [@bib26]). Overall, we identified and quantified 87% and 92% of the known RC proteins and assembly factors in human and mouse cell lines, respectively. The expression levels of 40 of the 45 complex I subunits were significantly reduced in UOK262 cells compared to UOK262pFH cells ([Figure S2](#mmc1){ref-type="supplementary-material"}A). Furthermore, complex II, complex III, and complex IV showed decreases in abundance of specific subunits ([Figure S2](#mmc1){ref-type="supplementary-material"}A). These data suggest that respiratory dysfunction in UOK262 cells is likely the product of a global downregulation in the content of RC complexes and their assembly factors. To investigate whether the downregulation of RC complexes occurred at a transcriptional level, we analyzed mRNA levels of RC transcripts using a previously published dataset ([@bib23]). We observed a global transcriptional downregulation of RC subunits in UOK262 compared to UOK262pFH ([Figure S2](#mmc1){ref-type="supplementary-material"}B). Interestingly, mtDNA-encoded RC subunits appeared upregulated in UOK262 ([Figure S2](#mmc1){ref-type="supplementary-material"}B), indicative of a possible compensatory increase in mitochondrial biomass due to the overall suppression of nuclear-encoded RC subunits.

To our surprise, there were no significantly depleted RC proteins in Fh1-deficient mouse cells ([Figure 3](#fig3){ref-type="fig"}A). Interestingly, SDH subunits showed increased expression over control, despite the fact that complex II makes no contribution toward respiration in Fh1-deficient cells ([Figure 1](#fig1){ref-type="fig"}C). Optical measurement of the functional content of complex III, cytochrome *c*, and complex IV ([@bib13], [@bib21]) confirmed that the content of complex III and cytochrome *c* does not change, and a 40% decrease in complex IV was observed ([Figure 3](#fig3){ref-type="fig"}B), although the latter is not reflected either by respiratory defects ([Figure 1](#fig1){ref-type="fig"}G) or by protein abundance ([Figure 3](#fig3){ref-type="fig"}A). These data suggest that the respiratory dysfunction in Fh1-deficient mouse cells cannot be explained by changes in RC complexes' abundance and could be ascribed to protein regulation at the post-translational level. Therefore, we decided to investigate whether post-translational modifications could explain the observed profound respiratory defects in mouse Fh1-deficient cells.Figure 3Abundance of RC Complex Subunits and Assembly Factors in Fh1-Deficient Mouse Cells(A) Quantitative profile of RC complex subunits and assembly factors in the indicated cell lines. The detected subunits and assembly factors are grouped by RC complexes. mtDNA-encoded subunits are indicated in red. The combined data of 4 biological replicates run over two independent TMT analyses are presented.(B) Functional content of complex III, cytochrome *c*, and complex IV in the indicated cell lines. Values are represented as mean ± SEM. Unpaired t test was used for statistics.

Succination Profile of Mitochondrial Protein in FH-Deficient Cells {#sec2.4}
------------------------------------------------------------------

Fumarate accumulation is responsible for a post-translation modification termed *succination*, which involves covalent bonding of fumarate to reactive cysteine residues of proteins ([@bib3], [@bib4], [@bib25], [@bib32]). We therefore studied the role of protein succination in the regulation of the activity of RC complexes. To this end, we applied a relative quantitative proteomic experiment using TMT. This non-targeted approach identified 563 (442 significantly changed, false discovery rate \[FDR\] \< 5%) succinated peptides in mouse cells ([Figure 4](#fig4){ref-type="fig"}A). Importantly, global succination decreased significantly after the restoration of Fh1 expression ([Figure 4](#fig4){ref-type="fig"}B), in line with the reduction in fumarate levels, and restored mitochondrial respiration observed in Fh1-reconstituted cells. While no RC subunits were identified in the succinated proteome, we identified succination of multiple components of the iron-sulfur (Fe-S) cluster biogenesis family of proteins. Succinated residues were detected on cysteine 213 of the Fe-S Cluster Scaffold Nfu1, on two cysteine residues (Cys-70 and Cys-139) of the Fe-S cluster assembly enzyme (Iscu), on cysteine 216 of bolA family member 1 (Bola1), and on cysteine 110 of Bola3 in Fh1-deficient cells ([Figure 4](#fig4){ref-type="fig"}A). Of note, none of these proteins exhibited significant alterations in their protein levels ([Figure 4](#fig4){ref-type="fig"}C). We then focused on Nfu1, which was the most significantly succinated protein among the ones involved in Fe-S cluster biogenesis ([Figure 4](#fig4){ref-type="fig"}A). Importantly, Fh1 re-expression significantly decreased Nfu1 succination in *Fh1*^−/−^*+pFh1-GFP* cells ([Figure 4](#fig4){ref-type="fig"}D) to a level comparable to *Fh1*^*fl/fl*^ ([Figures 4](#fig4){ref-type="fig"}D and 4F). To confirm the link between fumarate accumulation and succination of Fe-S cluster proteins, we performed a similar proteomic analysis in human cells. Here we detected 862 (639 significantly changed, FDR \< 5%) peptides in human FH-deficient cells ([Figure S2](#mmc1){ref-type="supplementary-material"}C). Strikingly, we identified NFU1 as one of the succinated proteins in UOK262 cells, and its levels of succination were rescued upon FH expression in UOK262pFH ([Figure S2](#mmc1){ref-type="supplementary-material"}C).Figure 4Fumarate-Mediated Succination of Fe-S Cluster Biogenesis Enzymes(A) Volcano plot illustrating the quantitative profile of identified mouse succinated peptides found in *Fh1*^−/−^ (both knockout \[KO\] clones) compared to *Fh1*^*fl/fl*^ cells. Nfu1, Iscu, Bola1, and Bola3 succinated peptides are indicated. Red dots indicate significantly regulated succinated peptides in Fh1-deficient cells compared to Fh1-proficient cells.(B) Polynomial curve representing the distribution of the intensity of succination signal in mouse cells (x) versus counts (y).(C) Scatterplot showing the levels of total protein changes compared to changes in succination. The succinated peptides display high fold changes (x axis) whereas the respective total protein levels remain mostly unchanged (y axis). The succinated peptides from Iscu, Nfu1, Bola1, and Bola 3 proteins are indicated.(D) Volcano plot of succinated peptides in *Fh1*^−/−^*+pFh1-GFP* compared to *Fh1*^*fl/fl*^.(E) Volcano plot of succinated peptides in *Fh1*^−/−^ compared to *Fh1*^−/−^*+pFh1-GFP*.(F) Bar graph indicating the reporter intensity relative to the Nfu1 succinated peptide containing C213 in the indicated cell types. Values are represented as mean ± SEM. One-way ANOVA test followed by Sidak's multiple comparison test was applied to assess the difference in the groups. n.s., not significant.(G) Aconitase activity in Fh1-deficent cells (3 biological replicates, values represents mean ± SEM). One-way ANOVA test followed by Dunnett's multiple comparison test was applied to assess the difference in the groups.(H and I) FACS profile (H) and fluorescence intensity of Venus-positive cells (I) of cells of the indicated genotype transfected with mito-Venus-GRX2.

The cysteine residues of Iscu and Nfu1 affected by succination are critical for their enzymatic activity. Consistently, mutations in these enzymes lead to defects in the early steps of Fe-S biosynthesis and varying degrees of deficiency of the RC complexes ([@bib17], [@bib20]). Therefore, we hypothesized that succination of Iscu/Nfu1/Bola1-3 would, at least in part, explain the mitochondrial respiratory defects observed in Fh1-deficient cells. Other mitochondrial enzymes, including aconitase 2 (Aco2), require correct Fe-S assembly for their function and can be used as a beacon for Fe-S cluster biogenesis. Therefore, to validate the downstream effect of Fe-S imbalance in our cells lines, we measured the activity of Aco2. Consistently, Aco2 activity was significantly decreased in Fh1-deficient cells ([Figure 4](#fig4){ref-type="fig"}G). To further demonstrate a defect in the biogenesis of the Fe-S cluster, we used mito-Venus-GRX2, a well-established probe whose fluorescence depends on the abundance of mitochondrial Fe-S clusters ([@bib11]). Importantly, mito-Venus-GRX2 fluorescence, which exhibited a typical mitochondrial staining ([Figure S1](#mmc1){ref-type="supplementary-material"}I), was markedly reduced in Fh1-deficient cells ([Figures 4](#fig4){ref-type="fig"}H and 4I). Together, these data suggest that succination of the Fe-S cluster promoted by fumarate leads to defects in Fe-S cluster biogenesis, which could explain the defects in RC complex I that we determined in FH-deficient cells.

Mitochondrial Potential Maintenance in FH-Deficient Cells {#sec2.5}
---------------------------------------------------------

To investigate whether the observed RC defects have a functional consequence on mitochondrial bioenergetics, we used the potentiometric probe tetramethyl rhodamine ethyl ester (TMRE) to measure the mitochondrial membrane potential. Surprisingly, FH-deficient cells showed a higher accumulation of TMRE in the matrix than their FH-proficient counterparts ([Figure 5](#fig5){ref-type="fig"}A), suggesting that they have a higher mitochondrial membrane potential (*ΔΨ*) despite having substantial defects in RC activity. To further investigate these findings, we set out to quantify the *ΔΨ* and the pH gradient (*ΔpH*) across the inner mitochondrial membrane, using multi-wavelength spectrophotometry ([@bib13], [@bib21]). This analysis revealed that, while *ΔΨ* is indeed elevated in these cells, in line with our imaging analyses, *ΔpH* is decreased ([Figure 5](#fig5){ref-type="fig"}B) such that the proton motive force (*ΔP*), which is the sum of the two, remains constant. The decrease in *ΔpH* is consistent with a decreased matrix pH. Given that the activity of the TCA cycle does not change the pH of the matrix per se, because protons there generated are consumed by the electron transport chain (ETC), it is likely that the high matrix concentration of fumarate and the associated H^+^ are major contributors to matrix pH.Figure 5Fh1-Deficient Cells Display Normal *ΔP* but Altered *ΔpH* and ΔΨ(A) TMRE and MTG staining and quantification in the indicated cell lines. Values are presented as mean ± SEM (MTG) or mean ± SD (TMRE). One-way ANOVA test was applied using Bonferroni multiple comparison test for mouse cells. Unpaired t test was used for UOK262/pFH cells.(B and C) Multi-wavelength spectrophotometric determination of *ΔΨ*, *ΔpH*, and *ΔP* (B) and of the redox state of the ubiquinone/ubiquinol couple, cytochrome *c*, and the NAD^+^/NADH couple (C). Values are presented as mean ± SEM. Unpaired t test was applied. For the *ΔpH* graph, 61 mV = 1 pH unit difference.(D) Respirometry coupled with multi-wavelength spectrophotometric determination of the flux of electrons through complex III. Data were obtained from at least 3 independent cultures and presented as mean ± SEM. Unpaired t test was applied to assess the difference in the groups. n.s., not significant.

The spectrophotometry approach also revealed that, while the redox potentials of the NAD^+^/NADH couple and cytochrome *c* are not significantly different, the ubiquinone/ubiquinol couple is markedly more oxidized in Fh1-deficient cells ([Figure 5](#fig5){ref-type="fig"}C), consistent with combined defects for complexes I and II; and it confirmed that the electron flux, measured as the number of electrons transferred per complex III per second, is decreased in Fh1-deficient cells ([Figure 5](#fig5){ref-type="fig"}D). Together, these results indicate that the overall flux of electrons through the RC is decreased in Fh1-deficient cells and that there is a different contribution of *ΔΨ* and *ΔpH* to *ΔP*.

Finally, to test whether FH-deficient cells are less dependent on mitochondrial function for cell survival, we treated FH-deficient cells with a number of RC inhibitors and measured cell growth. As expected from cells adapted to mitochondrial dysfunction, mouse and human FH-deficient cells were more resistant to RC inhibition ([Figures 6](#fig6){ref-type="fig"}A and [S3](#mmc1){ref-type="supplementary-material"}A) and their growth was unimpeded in low-oxygen conditions ([Figures 6](#fig6){ref-type="fig"}B and [S3](#mmc1){ref-type="supplementary-material"}B). Of note, Fh1-deficent cells were resistant to metformin and rotenone, confirming that complex I is not completely functional. Interestingly, mouse Fh1-deficient cells were sensitized to RC inhibitors in the presence of oligomycin ([Figures 6](#fig6){ref-type="fig"}C), consistent with the fact that they still need some contribution of complex V for ATP generation.Figure 6Fh1-Deficient Cells Are Resistant to RC Inhibition and Hypoxia(A--C) Proliferation profile of the indicated cell lines in the presence of various ETC inhibitors (A), in 21% and 1% oxygen conditions (B), or in response to the indicated mitochondria inhibitors (C). Data were obtained from at least 2 independent cultures and presented as mean ± SD.

Discussion {#sec3}
==========

There is increasing recognition that alterations in cellular metabolism underlie crucial aspects of oncogenesis. The clearest examples of this are seen from mutations in FH, SDH, and isocitrate dehydrogenase (IDH1/2), which give rise to accumulation of the oncometabolites fumarate, succinate, and 2-hydroxyglutarate, respectively ([@bib5], [@bib8], [@bib18], [@bib27]). In fact, tumor-associated cellular properties can be elicited by treatment with these oncometabolites in the absence of tumorigenic mutations ([@bib14], [@bib23]). Another well-documented and highly prevalent feature of tumor metabolism is the observation that respiratory dysfunction often accompanies the Warburg effect, which is recognized as a pervasive feature of tumors. In this study, we sought to provide a mechanistic link among FH loss, the accumulation of fumarate, and the ensuing mitochondrial dysfunction.

FH loss impairs TCA cycle activity and decreases the rate at which NADH and succinate are generated for use by the RC, decreasing oxygen consumption even if the RC components are functional. Thus, loss of FH activity would be expected to result in a loss of electrons (oxidation) from the mitochondrial NAD^+^/NADH and fumarate/succinate pools. Yet, this hypothesis has not been formally tested. Here, we performed a comprehensive bioenergetics analysis of mouse Fh1-deficient cells and observed a modest (≈16 mV) oxidation in the NAD^+^/NADH pool ([Figure 5](#fig5){ref-type="fig"}C), and oxidation of the fumarate/succinate pool was inferred from the increase in cytosolic fumarate. These cells also maintain the same *ΔP* as Fh1-proficient cells, that is, there is the same amount of energy available for ATP generation by the ATP synthase in both cell types. Oxygen consumption and ATP production are tightly coupled by the relative stoichiometry of the proton-pumping complexes and the ATP synthase, such that a decrease in oxygen consumption and electron flux implies a decrease in mitochondrial ATP production. As the rate of ATP production and consumption must also be matched, the results imply either that the Fh1-deficient cells have decreased ATP demand or that the shortfall is made up by increased glycolysis and glycolytic ATP production. The latter scenario is corroborated by previous analyses ([@bib9], [@bib31]).

The observation that the oxidation in the UQ/UQH~2~ (≈39 mV) is much more substantial ([Figure 5](#fig5){ref-type="fig"}C) than the oxidation in the NAD^+^/NADH pool is consistent with combined defects with complex I and complex II. Indeed, measurement of RC activity showed that complex I activity is decreased in both human and mouse FH-deficient cells, due to incomplete formation and assembly of the Fe-S clusters because of succination of proteins involved in Fe-S cluster biogenesis, including Iscu, Bola1-3, and Nfu1. Although in human cells we confirmed the succination of NFU1, in these cells we also observed a general suppression of nuclear-encoded mitochondrial genes, which likely contributes the observed respiratory defects. We also demonstrated that complex II activity is lowered by product inhibition due to aberrant fumarate accumulation. Complex II contains three Fe-S clusters; therefore, the observation that its activity is intact, when assessed in cell extracts of Fh1-deficient cells, indicates that the defects in Fe-S cluster generation are modest and affect complex I, which contains the highest number of Fe-S clusters among RC complexes, more strongly than complex II. The observed upregulation of SDH assembly factors could also compensate for the decrease in Fe-S cluster biogenesis, increasing the efficiency of their incorporation in the mature protein.

Several reasons could explain the different mitochondrial profiles of human and mouse cells. First, the human cells express a mutant FH ([@bib31]) whose role and function is not completely understood, while the mouse cells are knocked out for Fh1. Also, the different succination profile of Fe-S cluster biogenesis proteins could be explained by the different levels of accumulation of fumarate in these different cell lines ([@bib33]). In this scenario, NFU1 seems to be more susceptible to succination than Iscu and Bola1/3. Interestingly, Nfu1 succination was identified in T cells treated with fumarate derivatives ([@bib6]), confirming its vulnerability to succination. The hypothesis that mouse cells exhibit stronger defects in Fe-S cluster biogenesis is also confirmed by the fact that they exhibit inhibition and succination of Aco2 ([@bib25]), while human cells appear to have intact aconitase activity, as indicated by their ability to perform reductive carboxylation ([@bib16]). Although the decrease of Aco2 activity has been previously ascribed to succination of cysteine residues involved in Fe-S binding ([@bib25]), the availability of these residues for succination is more likely the consequence of an early defect in Fe-S assembly. Finally, additional mutations could be present in UOK262 cells, which could explain the transcriptional suppression of mitochondrial enzymes that we observed. These results are similar to those observed in another HLRCC cell line, UOK268, where a genetic suppression of all RC components was observed ([@bib31]). Therefore, more work is required to fully understand the determinants of this transcriptional reprogramming in these cells.

In conclusion, our comprehensive characterization of mitochondrial function in mouse and human FH-deficient cells showed that the loss of a single TCA cycle enzyme is sufficient to alter RC activity via multiple mechanisms, underlining the complex feedback system that controls mitochondrial function in pathophysiological conditions. Interestingly, the metabolic phenotype of FH-deficient cells can more effectively resist conditions that are otherwise unfavorable for mitochondrial function, including hypoxia, suggesting that these changes might be selected during tumor progression.

Experimental Procedures {#sec4}
=======================

Cell Culture {#sec4.1}
------------

Cells were cultured in media supplemented with 10% heat-inactivated fetal bovine serum (FBS). Mouse cells were cultured in high-glucose DMEM (41966, Gibco) supplemented with uridine at a final concentration of 50 μg/mL (Sigma). UOK262 and UOK262pFH cells were cultured in the same medium as *Fh1* cells but without supplemental uridine. For hypoxia experiments, cells were initially grown in normoxia for 24 hr and then transferred into 1% oxygen in an InViVO2 Hypoxia Workstation 500, for the indicated amount of time.

Cell Counting in 21% and 1% O~2~ {#sec4.2}
--------------------------------

Equal numbers of cells were seeded in 6-well plates and cultured in either 21% or 1% O~2~ conditions. At the indicated time points, cells were trypsinized and counted on a Vi-CELL XR (Beckman Coulter), and viability was assessed by the exclusion of trypan blue dye.

Proliferation on Galactose and ETC Inhibitors {#sec4.3}
---------------------------------------------

Proliferation of cells in the presence of various ETC inhibitors or glucose-deficient medium supplemented with galactose was monitored using an IncuCyte Zoom instrument (Essen Bioscience).

Multi-wavelength Spectrometry {#sec4.4}
-----------------------------

Heme absorption and NADH fluorescence measurements have been described previously ([@bib21]). In brief, cells were cultured in T175 flasks in phenol red-free DMEM. The cells were washed twice with PBS, detached with TripLE Express (Themo Fisher Scientific), and then the TrypLE was quenched with DMEM supplemented with 10% FBS. Cells were spun down at 500 × *g* for 5 min and re-suspended in FluoroBrite DMEM (Themo Fisher Scientific) supplemented with 4 mM glutamine at a density of 10^7^ cells/mL. Studies were carried out in a stirred 5-mL chamber maintained at 37°C. Oxygen consumption, at constant oxygen tension, was calculated from the rate of the diffusion of oxygen across 80 mm of fine-bore oxygen-permeable silicone tubing immersed in the cell suspension. Optical spectra were collected on two time-multiplexed 0.3-m spectrographs (Triax 320; Horiba, Edison, NJ), each equipped with a 1,024 × 128 pixel back-thinned charge-coupled device camera (DV401BV; Andor Technology, SouthWindsor, CT). NADH fluorescence was excited with a high power 365 nm LED (Nichia, Japan), and spectra were collected between 390 and 661 nm using a 300-g/mm grating blazed at 500 nm with the slits set to a spectral resolution of 10 nm. The cell suspension was illuminated with a high-power cool white LED (Lumileds, USA), and heme absorption spectra were collected between 509 and 640 nm using a 600-g/mm grating blazed at 500 nm with slits set to a spectral resolution of 1 nm.

The contribution of each heme/fluorophore to the spectra was calculated using linear multi-wavelength least-squares fitting. The oxidation state and content of the hemes and the oxidation state of mitochondrial NADH pool were back-calculated from the fully reduced state and the fully oxidized state. The fully reduced state was obtained by making the cells anoxic for 2 min at the beginning of the study, and the mitochondrial NADH pool was fully oxidized by inhibiting the TCA cycle with 1 mM of the complex II inhibitor 3-nitropropionic acid and adding 1 μM carbonyl cyanide m-chlorophenyl hydrazine (CCCP) at the end of the study. The hemes were fully oxidized by the subsequent addition of 1 μM rotenone. The residual oxygen consumption after the addition of rotenone was assumed to be non-mitochondrial and subtracted from the total oxygen consumption to give the mitochondrial oxygen consumption. The electron flux through complex III was calculated by scaling the mitochondrial oxygen consumption by 4 electrons per O~2~ and normalizing to the content of complex III measured from the content of the *b*-hemes. The redox potentials of the mitochondrial NAD^+^/NADH pool and cytochrome *c* were calculated from the Nernst equation with midpoint potentials of −320 and + 260 mV, and the former was corrected for the pH of the matrix using the pH gradient assuming the cytosol remained at pH 7.0. The redox potentials of the ubiquinone pool, the membrane potential (Δψ), and the pH gradient (ΔpH) were calculated from the redox poise of complex III, as described previously ([@bib13]). The proton motive force (Δp) is the sum of Δψ and ΔpH.

Proteomic Analysis {#sec4.5}
------------------

### Sample Dissolution and Protein Digestion {#sec4.5.1}

Cell pellets were dissolved in 0.1% SDS and 0.1 M Triethylammonium bicarbonate (TEAB) followed by probe sonication. Protein concentration was measured with the Quick start Bradford assay (Bio-Rad). A total 90 μg protein per sample was reduced with 2 μL 50-mM tris-2-carboxymethyl phosphine (TCEP) (Sigma) at 60°C for 1 hr. Cysteine residues were blocked with 1 μl 200-mM methyl methanethiosulfonate (MMTS) (Sigma) for 10-min incubation at room temperature. For protein digestion, 6 μl trypsin solution (Roche) in 0.1% F.A (500 ng/μL) was added to each sample for overnight proteolysis.

### TMT Labeling and bRP Fractionation {#sec4.5.2}

TMT10plex labeling reagents (Thermo Scientific) were reconstituted in 41 μL anhydrous acetonitrile and transferred to each sample followed by incubation for 1 hr at room temperature. The reaction was quenched with 8 μL 5% hydroxylamine. The peptide mixture was fractionated with high-pH reversed-phase chromatography on a C18 column (Waters, X-bridge). Mobile phase (A) was composed of 20 mM ammonium hydroxide and mobile phase (B) was composed of 80% acetonitrile and 20 mM ammonium hydroxide. The gradient elution method at a flow rate of 200 μL/min was as follows: for 10 min gradient up to 5% (B), for 35 min gradient up to 35% (B), for 10 min up to 50% (B), for 10 min up to 95% (B), for 10 min isocratic to 95% (B), for 5 min down to 5% (B), and for 10 min isocratic equilibration 5% (B) at 40°C. Fractions were collected in a peak-dependent manner and were dried with a vacuum concentrator.

### Liquid Chromatography-Mass Spectrometry Analysis {#sec4.5.3}

The peptide fractions were analyzed on a Dionex Ultimate 3000 UHPLC system coupled with Q-Exactive mass spectrometer (Thermo Scientific). The RP fractions were reconstituted in 40 μL loading solution (2% acetonitrile and 0.1% formic acid), and a 4-μL volume was loaded on the Acclaim PepMap 100, 100 μm × 2 cm C18, 5 μm, 100 Ȧ trapping column with the ulPickUp Injection mode using the loading pump at a 4 μL/min flow rate for 10 min. For the peptide separation, the Acclaim PepMap RSLC, 75 μm × 50 cm, nanoViper, C18, 3 μm, 100 Ȧ column retrofitted to an easy source was used for multi-step gradient elution. Mobile phase (A) was composed of 2% acetonitrile, 0.1% formic acid, and 5% DMSO and mobile phase (B) was composed of 80% acetonitrile, 0.1% formic acid, and 5% DMSO. The gradient elution method at a flow rate of 300 nL/min was as follows: for 10 min gradient up to 5% (B), for 85 min gradient up to 45% (B), for 5 min up to 95% (B), for 8 min isocratic to 95% (B), for 2 min down to 5% (B), and for 10 min isocratic equilibration 5% (B) at 40°C. The top 10 precursors were selected with Fourier transform (FT) mass resolution of 70,000 and isolated for higher-energy collisional dissociation (HCD) fragmentation with collision energy of 33 and FT resolution of 35,000.

### Database Search {#sec4.5.4}

The acquired tandem mass spectrometry (MS/MS) mass spectra were processed with SequestHT implemented on the Proteome Discoverer software version 2.1 for peptide and protein identifications against a UniProtKB/Swiss-Prot fasta file containing 21,530 reviewed human entries or 17,000 reviewed mouse entries. The SequestHT node included the following parameters: Precursor Mass Tolerance 20 ppm, Fragment Mass Tolerance 0.02 Da, Dynamic Modifications were Oxidation of M (+15.995 Da), Deamidation of N, Q (+0.984 Da), Methylthio of C (+45.988), and 2-succinyl cysteine (+116.011). The Static Modifications were TMT6plex at any N terminus and K (+229.163 Da). The level of confidence for peptide identifications was estimated with the Percolator node with decoy database search. FDR was set at 0.01 based on q-value. The Reporter Ion Quantifier node included a custom TMT 10plex (Thermo Scientific Instruments) Quantification Method, integration window tolerance of 20 ppm, and the Most Confident Centroid integration method.

### Statistical Analysis {#sec4.5.5}

Protein quantification was normalized on total peptide amount, and the FH-deficient conditions were compared to the wild-type (WT) FH cells with ANOVA test using the Perseus proteomics data analysis tool ([@bib28]). Significant hits were filtered using permutation-based FDR (\<1% for total proteome and \<5% for succinylated peptides). Volcano plots and scatterplots were drawn in R studio using the ggplot2 package. Heatmaps of proteomics data from mouse and human cells were generated with R studio.

RNA Sequencing Analyses {#sec4.6}
-----------------------

RNA sequencing (RNA-seq) data of UOK262 and UOK262-pFH cells (GEO: [GSE77542](ncbi-geo:GSE77542){#intref0015}) were obtained from [@bib23]. Data were log normalized using the R package DEseq2, and gene expression data of RC complexes were plotted with heatmap representation.

Respirometry Experiments {#sec4.7}
------------------------

All respirometry measurements were performed using an XFe24 Analyzer (Agilent Technologies, formerly Seahorse Bioscience) according to the manufacturer's instructions. For experiments on intact cells, injections of various compounds were performed as indicated in the figures. For experiments on permeabilized cells, cell membranes were permeabilized using the Seahorse XF Plasma Membrane Permeabilizer (PMP) reagent according to the manufacturer's instructions. The contribution of each complex to respiration was determined by injections of various compounds, as described by [@bib22]. Following all respirometry measurements, cells in each well were disrupted in radioimmunoprecipitation assay (RIPA) buffer and protein was measured using the bicinchoninic acid (BCA) assay (Thermo Fisher Scientific). Oxygen consumption rates from each well were normalized to the protein abundance of that well or to the average of the wells relative to that group.

Complex I Activity Assay {#sec4.8}
------------------------

Complex I in-gel flavin-site activity assay was measured as indicated in [@bib29] using 100 μg isolated mitochondria separated in NativePAGE 3%--12% Bis-Tris Gel System. Gels were scanned and the intensity of complex I activity was measured using ImageJ. Respiration mediated by complex I on isolated mitochondrial membranes from bovine heart was measured as described in [@bib7].

SQR Assay {#sec4.9}
---------

SQR measurements were performed as described by [@bib24] with minor modifications. Cells were permeabilized with 0.1% v/v Triton X-100 in a buffer with 25 mM KHPO~4~ (pH 7.4), 1--25 mM succinate, 50 μM decylubiquinone, 5 μM rotenone, 2 μM antimycin A, and 10 mM NaN~3~. Different concentrations of fumarate were also included in the buffer, as indicated in the figures. After a 15-min incubation at room temperature, a baseline absorbance at 600 nm was measured and the reaction started by adding 100 μM 26-dichlorophenolindophenol (DCIP) (ϵ = 21 mM^−1^ cm^−1^). The change in absorbance was monitored for 2 min before and after the addition of 50 μM 2-thenoyltrifluoroacetone (TTFA), a complex II inhibitor used to confirm reaction specificity. The TTFA-sensitive SQR activity is reported as nmol/min DCIP/0.6 × 10^6^ cells. Fumarate levels at the end of SQR experiments were measured by ^1^H nuclear magnetic resonance (^1^H NMR) spectroscopy. This was performed with solvent suppression on a 600-MHz Brucker Avance NMR spectrometer. 4,4-dimethyl-4-silapentane-1-sulfonic acid (DSS) was used as an internal standard, and the Electronic Reference to Access In Vivo Concentration (ERETIC) method ([@bib2]) was used to determine the concentration of DSS in each sample. Processing of NMR spectra included both zero- and first-order phase corrections followed by baseline correction using the Chenomx NMR Suite 7.6. Fumarate was identified, based on chemical shift assignment, also using the Chenomx NMR Suite 7.6. The concentration of fumarate was determined by normalizing peak area to a known concentration of DSS in each sample.

Flow Cytometry Measurements {#sec4.10}
---------------------------

6 × 10^5^ cells were plated onto 6-cm dishes. The day after, cells were transfected using Lipofectamine 2000, following the manufacturer's instructions and Fe-S constructs N173-GRX2 and C155-GRX2 as described before ([@bib11]). After 48 hr, cells were washed in PBS and detached using trypsin. After centrifugation at 1,000 × *g* for 5 min, cells were resuspended in complete medium and analyzed by fluorescence-activated cell sorting (FACS) using an LSR II flow cytometer (BD Biosciences). Venus fluorescence was measured using a 488-nm laser for excitation using 50-mW power; emission was measured using a (488) 530/30 detector. 1 × 10^5^ events were acquired for each sample. Graphs presented were generated using FlowJo software.

Aconitase Activity Assay {#sec4.11}
------------------------

The activity of aconitase in Fh1-deficient cells was measured using the Aconitase Assay Kit (Cayman), following the manufacturer's instruction.

Microscopy {#sec4.12}
----------

Cells were grown in μ-Slide 8 Well vessels (ibidi) in medium without phenol red. Live cells were stained with 50 nM MitoTracker Green (MTG) (Invitrogen) and 10 nM TMRE (Invitrogen) for 1 hr at 37°C in complete media with 25 mM HEPES (pH 7.4). Cells were maintained at 37°C and 5% CO~2~ in a stage top incubator (Tokai Hit). Images were acquired using a Leica TCS SP5 (Leica Microsystems, Wetzlar, Germany) equipped with a 20× objective. Acquisition was performed in a sequential scanning mode. MTG was excited using the 488-nm laser and TMRE using the 543-nm laser. MTG emission was collected from 500 to 545 nm and TMRE emission from 580 to 620 nm. TMRE intensity from images was quantified using Columbus Image Data Storage and Analysis System (PerkinElmer). For mito-Venus-GRX2 constructs, 8 × 10^4^ or 1 × 10^5^ cells were plated on Nunc Lab-Tek Chambered Coverglass (1.0 borosilicate glass). The day after, cells were transfected with Lipofectamine 2000 (Invitrogen), following the manufacturer's instructions, and mito-Venus Fe-S sensor constructs N173-GRX2 and C155-GRX2. After 16 hr, medium was replaced with a fresh one and images were acquired using a Leica TCS SP5 (Leica Microsystems, Wetzlar, Germany) equipped with a 63× oil UV objective. The Venus construct was excited using Argon laser (514 nm) as described before ([@bib11]). Microscope settings were kept constant during the acquisition of all images.

Statistical Analysis {#sec4.13}
--------------------

Statistical analyses were performed in GraphPad Prism 6 software. Pairwise comparisons were assessed using an unpaired two-tailed Student's t test. Multiple comparisons were assessed with one-way ANOVA, including Tukey post hoc test for multiple testing, if not indicated otherwise. Error bars are shown as indicated in figure legends and all experiments were performed at least twice.
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